Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers
Faraat Ali, Kumari Neha, Garima Chauhan
Topics & Concepts
MedicineCancer researchMarketing authorizationMedullary thyroid cancerDrug developmentCancerAuthorizationInternal medicineOncologyPharmacologyDrugThyroid cancerBioinformaticsBiologyComputer securityComputer scienceLung Cancer Treatments and MutationsLung Cancer Research StudiesAdvanced Breast Cancer Therapies